Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock Has Consensus Price Target of $30.91

Key Points

• Analysts maintain a Moderate Buy consensus on Bicara Therapeutics, with 10 buy, two strong-buy, three hold, and two sell ratings. The average 12-month price target is $30.91, though recent targets range from $23 to $39.
• BCAX opened at $9.13, near its one-year low of $8.36 and well below its one-year high of $30.99. The company reported an adjusted quarterly loss of $0.82 per share, in line with estimates, while analysts expect a full-year loss of $3.49 per share.
• Company insiders sold 58,750 shares worth approximately $1.55 million over the past 90 days under pre-arranged trading plans. Meanwhile, several institutional investors initiated or increased positions, including Jupiter Topco with an investment of roughly $94 million.

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $30.91.

A number of equities research analysts recently commented on the stock. Wedbush reduced their price objective on shares of Bicara Therapeutics from $33.00 to $24.00 and set an "outperform" rating for the company in a research report on Thursday. Wells Fargo & Company boosted their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 12th. BTIG Research reissued a "buy" rating and set a $39.00 target price on shares of Bicara Therapeutics in a research note on Monday, October 19th. BMO Capital Markets assumed coverage on Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $35.00 price objective for the company. Finally, Citigroup reiterated a "market outperform" rating on shares of Bicara Therapeutics in a research report on Friday, August 21st.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $9.13 on Friday. The stock has a market capitalization of $604.13 million, a P/E ratio of -2.95 and a beta of -0.70. The company's fifty day moving average is $19.74 and its two-hundred day moving average is $21.16. Bicara Therapeutics has a 1 year low of $8.36 and a 1 year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). Sell-side analysts predict that Bicara Therapeutics will post -3.49 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Ryan Cohlhepp sold 17,500 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer directly owned 181,641 shares of the company's stock, valued at $4,159,578.90. This represents a 8.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 12,500 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the sale, the chief financial officer owned 129,855 shares of the company's stock, valued at $3,632,044.35. This trade represents a 8.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 58,750 shares of company stock worth $1,554,800. Corporate insiders own 13.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. Jupiter Topco LLC purchased a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $93,957,000. Bank of America Corp DE acquired a new position in Bicara Therapeutics during the second quarter worth $10,478,000. Palo Alto Investors LP acquired a new position in Bicara Therapeutics during the second quarter worth $16,341,614. Walleye Capital LLC acquired a new position in Bicara Therapeutics during the second quarter worth $10,487,000. Finally, Dimensional Fund Advisors LP boosted its position in Bicara Therapeutics by 166.9% during the first quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company's stock worth $2,170,000 after purchasing an additional 68,327 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company's approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara's lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.